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In adult mammals, the regeneration of the optic nerve is very limited and at the moment there
are several groups trying different approaches to increase retinal ganglion cell (RGC) survivalAvailable online 6 September 2014
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and axonal outgrowth. One promising approach is cell therapy. In previous work, we performed
intravitreal transplantation of bone-marrow mononuclear cells (BMMCs) after optic nerve crush
in adult rats and we demonstrated an increase in RGC survival and axon outgrowth 14 days
after injury. In the present work, we investigated if these results could be sustained for a longer
period of time. Optic nerve crush was performed in Lister-hooded adult rats and BMMC or saline
injections were performed shortly after injury. Neuronal survival and regeneration were
evaluated in rats' retina and optic nerve after 28 days. We demonstrated an increase of 5.2
fold in the axon outgrowth 28 days after lesion, but the BMMCs had no effect on RGC survival. In
an attempt to prolong RGC survival, we established a new protocol with two BMMC injections,
the second one 7 days after the injury. Untreated animals received two injections of saline. We0
rved.
Carlos Chagas Filho, Centro de Ciências da Saúde, Sala G2-028, Cidade Universitária, RJ
2280 8193.
averucha-do-Valle).
b r a i n r e s e a r c h 1 5 8 7 ( 2 0 1 4 ) 5 4 – 6 8 55observed that although the axonal outgrowth was still increased after the second BMMC
injection, the RGC survival was not signiﬁcantly different from untreated animals. These results
demonstrate that BMMCs transplantation promotes neuroregeneration at least until 28 days
after injury. However, the effects on RGC survival previously observed by us at 14 days were not
sustained at 28 days and could not be prolonged with a second dose of BMMC.
& 2014 Elsevier B.V. All rights reserved.1. Introduction
It is well described that in adult mammals most of the retinal
ganglion cells (RGCs) fail to regenerate their axons after optic
nerve crush or transection and undergo apoptosis. This
regeneration failure has been attributable both to the inhibi-
tory environment of the central nervous system and the
intrinsic inability of RGCs to regenerate (Schwab et al., 1993;
Goldberg, 2004). Because of that, many groups have been
testing different approaches in order to promote RGC survival
and axonal outgrowth following optic nerve injury.
Among these approaches, there is induction of inﬂammation
either by lens puncture or Zymosan injection (Fischer et al., 2000;
Leon et al., 2000; Yin et al., 2003) and the stimulation of RGCs
intrinsic program to regenerate through, for example, the dele-
tion of the phosphatase and tensin (PTEN) (Park et al., 2008)
and/or the deletion of the homolog suppressor of cytokine
signaling 3 (SOCS3) (Smith et al., 2009; Sun et al., 2011). The
combination of PTEN deletion with Zymosan injection and
elevation of intracellular cAMP leads to long distance regenera-
tion and functional recovery (Kurimoto et al., 2010; de Lima et al.,
2012).
However, these different approaches are not easily translated
to clinic. Regarding this, a developing strategy involves cell
therapy with the transplantation of bone marrow derived cells
or other cell types. Cell therapy has been used in different animal
models of neurological diseases and lesions with interesting
results (Giraldi-Guimaraes et al., 2009; Ribeiro-Resende et al.,
2009; Johnson et al., 2010; Moraes et al., 2012; Suzuki et al., 2012;
de Vasconcelos dos Santos et al., 2010; Vasconcelos-dos-Santos
et al., 2012) and it is beginning to be used in clinical trials
(Barbosa da Fonseca et al., 2009, 2010; Battistella et al., 2011;
Friedrich et al., 2012; Rost et al., 2012). Interestingly, data from
clinical studies suggests that an intravitreal injection of auto-
logous bone-marrow-derived cells into the vitreous cavity is
technically feasible and safe (Jonas et al., 2008, Siqueira
et al., 2011).
In the visual system, bone marrow mesenchymal cells
have been transplanted intravitreally in two different models
of glaucoma and showed neuroprotective results (Yu et al.,
2006; Johnson et al., 2010). It has also been shown that brain-
derived neurotrophic factor (BDNF)-secreting mesenchymal
cells increases RGC survival in chronically hypertensive rat
eyes (Harper et al., 2011) and that modiﬁed bone marrow
mesenchymal cells increased neuroprotection after optic
nerve transection (Levkovitch-Verbin et al., 2010). Increased
neuronal survival was also obtained after bone marrow
mesenchymal cells transplantation in a model of lesion by
ischemia/reperfusion (Li et al., 2009).In previous work, our group demonstrated increase in RGC
survival and axonal outgrowth 14 days after optic nerve crush
and BMMC transplantation (Zaverucha-do-Valle et al., 2011).
We have also identiﬁed two proteins—Tax1-binding protein 1
and Synaptotagmin IV—that were up-regulated after optic
nerve crush and cell therapy (Mesentier-Louro et al., 2012).
However, in most of these studies the effects were analyzed
14 days after treatment and it was important to investigate
whether BMMC transplantation effects could still be present
after a longer period of time. Therefore, in the present work,
we analyzed neuroprotection and axonal regeneration 28
days after nerve injury and BMMC transplantation.2. Results
2.1. BMMC transplantation increases axonal outgrowth
28 days after injury
To evaluate if the effect of BMMC transplantation on regen-
eration (Zaverucha-do-Valle et al., 2011) was sustained, we
analyzed the axonal outgrowth 28 days after injury and cell
therapy. For that, we used cholera toxin subunit B conjugated
to Alexa-488 (CTB) as anterograde marker to visualize axons.
In untreated animals (Fig. 1(A)), we observed a very small
number of axons crossing the injury site (n). After BMMC
transplantation, we noticed an increase in the number of
axons distal to the lesion (Fig. 1(B)) when compared with the
untreated group.
We quantiﬁed the number of CTB-labeled axons extending
to 0.5, 1.0, 1.5 and 2 mm from the crush site using the formula
described by Leon and co-workers (Leon et al., 2000). The
untreated animals had a median of 163.9 axons per nerve at
0.5 mm; 52.8 axons at 1 mm; 2.3 axons at 1.5 mm and 0 axons
at 2 mm from the crush site (n¼8). The animals that received
BMMC transplantation had a median of 819.2 axons per nerve
at 0.5 mm (n¼5); 454.9 axons at 1 mm (n¼5); 304.5 axons at
1.5 mm (n¼4) and 15.8 axons at 2 mm (n¼3) from the crush
site. BMMC transplantation generated a 5-fold signiﬁcant
increase (po0.01) in the number of CTB-labeled axons at
0.5 mm from the crush site, a 8.6-fold signiﬁcant increase
(po0.01) in the number of CTB-labeled axons at 1 mm from
the crush site and a 129.8-fold signiﬁcant increase (po0.05) in
the number of CTB-labeled axons at 1.5 mm from the crush
site. At the distance of 2 mm from the injury site, there was
no statistically signiﬁcant difference between the two condi-
tions (p40.05). Fig. 1(C) shows the quantiﬁed data.
These results were conﬁrmed by using GAP-43 staining. We
quantiﬁed the number of GAP-43þ axons located at 0.5, 1.0, 1.5
Fig. 1 – BMMC transplantation increases axonal outgrowth 28 days after optic nerve crush. (A) and (B) Photomontage of
confocal projection images of longitudinal sections of optic nerve labeled with CTB injected into the vitreous body 2 days
before euthanasia. Animals were analyzed 28 days after injury and saline injection (A) or BMMC transplantation (B). In
untreated animals (A), the axons do not extend much passing the injury site (*), while in treated animals, there is an increased
axonal extension (B). (C) Quantiﬁcation of the number of CTB labeled axons located at 0.5, 1, 1.5 and 2 mm from the crush site
28 days after the injury. (D) Quantiﬁcation of the number of GAP-43þ axons located at 0.5, 1, 1.5 and 2mm from the crush site
28 days after the injury. Graphs represent median and interquartile range. Scale bar: 125 μm.
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axons per nerve using the formula described by (Leon et al.,
2000). The untreated animals had a median of 220.9 axons per
nerve at 0.5mm (n¼3); 46.7 axons at 1mm (n¼8); 41 axons at
1.5mm (n¼3) and 0 axons at 2mm (n¼8) from the crush site.
The BMMC-treated animals had a median of 583.5 axons per
nerve at 0.5 mm (n¼4); 258.9 axons at 1mm (n¼10); 65.6 axons
at 1.5 mm (n¼5) and 21 axons at 2mm (n¼10) from the crush
site. We observed a signiﬁcant increase in the number of
GAP-43þ axons located at 1mm from the crush site after BMMC
transplantation. Fig. 1(D) shows the quantiﬁed data.2.2. The BMMC transplantation effect on RGC survival is
not sustained 28 days after injury
To evaluate if the effect of BMMC transplantation on neuro-
protection (Zaverucha-do-Valle et al., 2011) was also sus-
tained, we analyzed RGC survival 28 days after injury and
cell therapy. For that, we used the retrograde tracer DiI or the
antibody Tuj1. Fig. 2(A) illustrates DiI labeled RGCs and
virtually intact axonal bundles in the contralateral, uninjuredretinas. In contrast, twenty-eight days after optic nerve crush,
the number of surviving RGCs is very small, both in the
untreated and the treated conditions (Fig. 2(B) and (C)). Fig. 2(G)
shows the quantiﬁcation of the data. Untreated animals (n¼8)
showed a survival of 15.9571.78% RGCs and BMMC-treated
animals (n¼9) had a survival of 13.4571.18% RGCs compared to
contralateral uninjured retinas.
These results were conﬁrmed by using another technique
to label RGCs, the Tuj1 antibody. Using this technique, we can
notice that virtually all RGCs are labeled in the uninjured
retinas (Fig. 2(D)). After optic nerve crush, there is a great
reduction in the number of surviving RGCs, both in untreated
and treated conditions (Fig. 2(E) and (F)). Fig. 2(H) shows the
quantiﬁcation of the data. Untreated animals had 12.717
1.91% of Tuj1þRGCs and BMMC-treated animals had 11.587
2.19% of Tuj1þRGCs compared to contralateral uninjured
retinas. However, we observed that, in BMMC-treated retinas,
RGC cells stained with Tuj1 exhibit a typical morphology,
brighter staining and more intact axons in several of the
analyzed retinas (arrows and arrowheads in Fig. 2(E) and (F)),
suggesting that the treatment may have other beneﬁcial
effects that are not related to cell survival.
Fig. 2 – BMMC transplantation does not sustain RGC survival 28 days after optic nerve crush injury. (A)–(F) Confocal projection
images of ﬂat-mounted retinas retrograde labeled with DiI injected into the superior colliculus 7 days before the injury (A)–(C) or
labeled with Tuj1 antibody (D)–(F). (A) and (D) Control retina with no injury. We can notice a high number of RGCs and intact axonal
bundles. (B) and (E) Twenty-eight days after optic nerve injury, there is a great reduction in the number of RGCs (arrowheads) and
thinning of axon bundles (arrows). (C) and (F) In treated animals, the number of surviving RGCs is similar to untreated ones.
However, cell morphology (arrowheads) and integrity of axon bundles (arrows) revealed by Tuj1 staining are qualitatively better
preserved. (G) and (H) Quantiﬁcation of RGC survival 28 days after the crush using DiI retrograde labeling (G) or Tuj1 labeling (H). (% of
DiIþ or Tuj1þRGCs relative to normal). For DiI labeling, n¼8 (crushþsaline) and n¼9 (crushþBMMC). For Tuj1 labeling, n¼4
(crushþsaline) and n¼6 (crushþBMMC). Scale bar: 50 μm.
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ence on axonal outgrowth comparing treated to untreated
animals 28 days after injury, the number of surviving RGCs is
similar in both conditions. This suggests that there are
probably different mechanisms related to axon regeneration
and neuronal protection.2.3. Expression of trophic factors one day after optic nerve
crush
In order to investigate possible mechanisms related to the
observed effects, we analyzed mRNA levels of different
trophic factors that have been previously associated to optic
Fig. 3 – mRNA levels of trophic factors after optic nerve crush and cell therapy. Quantiﬁcation of FGF-2 (A), BDNF (B),
Oncomodulin (C), CNTF (D), VEGF (E) and mRNA levels by real time RT-PCR 1 day after injury. We can note that 1 day after
injury there is a signiﬁcant increase in FGF-2 mRNA levels after cell therapy (po0.05). Values of the graphs represent the
means 7 standard error of the mean. Values were normalized to the control group mean and GAPDH was used as loading
control.
Fig. 4 – FGF-2 expression in the retina 28 days after optic nerve crush. (A) and (B) Confocal photomicrographs of FGF-2
immunostaining in the retina 28 days after optic nerve crush and saline injection (A) or BMMC transplantation (C). In both
conditions, FGF-2 (red) is expressed in the inner nuclear layer (INL) and in the nerve ﬁber layer (NFL). Nuclei are
counterstained with TO-PRO-3 (blue). (C) Quantiﬁcation of FGF-2 labeling ﬂuorescence intensity 28 days after injury. Scale bar:
20 μm.
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(Sapieha et al., 2003), vascular endothelial growth factor
(VEGF)(Kilic et al., 2006) ciliary neurotrophic factor (CNTF)
(Weise et al., 2000; Muller et al., 2007; Muller et al., 2009),
BDNF (Mansour-Robaey et al., 1994; Isenmann et al., 1998;
Galindo-Romero et al., 2013) and oncomodulin (Yin et al.,
2006, 2009) by real time PCR 1 day after optic nerve crush.
We chose a time point when the BMMCs would still be
present to select a factor to be further analyzed 28 days after
the injury. Fig. 3 shows the quantiﬁed data. Values were
normalized with mRNA levels in control retinas and GAPDH
was used as loading control.
We can notice that there was a signiﬁcant increase in
FGF-2 mRNA levels (Fig. 3(A)) in BMMC-treated animals one
day after injury compared with untreated animals. For the
other analyzed factors, there were no statistically signiﬁcant
differences between treated and untreated animals.2.4. FGF-2 expression in the retina 28 days after optic
nerve crush
As the FGF-2 was the only analyzed factor that was up-
regulated after cell therapy one day after injury, we ana-
lyzed the expression of this factor in the retina 28 days
after the injury by imunohistochemistry. In previous work,
our group showed that there is an increase in FGF-2
expression in the treated animals 14 days after the crush
(Zaverucha-do-Valle et al., 2011) and we speculated that
this increase could be related to the BMMC effects on RGC
survival and axon outgrowth. After 28 days, we observed
FGF-2 expression both in the inner nuclear layer and in the
nerve ﬁber layer in both untreated (Fig. 4(A)) and treated
animals (Fig. 4(B)). We quantiﬁed the ﬂuorescence intensity
in the different retinal layers of untreated and BMMC-
treated animals, and we observed there was no difference
between the groups. This suggests that the increased
expression of FGF-2 in BMMC-treated animals observed 14
days after injury was not sustained. Fig. 4(C) shows the
quantiﬁed data.2.5. Transplanted cells do not remain in the eye for a long
period of time
To investigate the fate of transplanted cells, we used different
techniques. For short-term tracking, we either labeled the
BMMCs with a radioisotope (99mTc) and analyzed by scinti-
graphy or we labeled them with a ﬂuorescent dye (CellTrace)
and analyzed by ﬂow cytometry. Fig. 5 shows that 1 h after
optic nerve crush and cell transplantation 99mTc activity was
not found in any other organ of the body and was restricted
to the eye, suggesting that BMMCs do not enter the blood-
stream shortly after transplantation. This can be seen in the
sagittal (Fig. 5(A)), coronal (Fig. 5(B)) and horizontal (Fig. 5(C))
planes. In the transversal plane of the torax (Fig. 5(D)), we can
note the absence of activity in other organs. In Fig. 5(E) we
can see the 99mTc activity combined with a CT image. Because
of the short half-life of the 99mTc, its activity could not be
detected for a longer period of time.Animals that received CellTrace-labeled BMMCs were
analyzed one and three days after optic nerve crush and cell
transplantation by ﬂow cytometry. In Fig. 5(F) we can notice
that prior to transplantation, most of the BMMCs were
labeled with CellTrace, demonstrating the efﬁciency of label-
ing. In Fig. 5(G) we can see that there is no unspeciﬁc staining
in uninjured eyes and in Fig. 5(H) and (I) there is a huge
decrease in the number of transplanted cells in the eye of the
host from one (Fig. 5(H)) to three days (Fig. 5(I)) after the
injection.
For a long-term tracking, we labeled the BMMCs with SPION
and analyzed them by in vivo MRI 1, 5 and 14 days after optic
nerve crush and cell transplantation. In Fig. 6(A)–(D), we can
see the dextran-coating (in green) of the dissociated BMMC
labeled with SPION before transplantation. Nuclei are stained
with TO-PRO-3 (in green). We can note that although the
efﬁciency of SPION incorporation seems high, each cell can
only incorporate a few particles. In Fig. 6(E), we can see that
one day after optic nerve crush and BMMC injection, there is a
high number of dextran-labeled cells (in red) in the vitreous
body. Nuclei are stained with TO-PRO-3 (in green).
Fig. 6(F) shows MRI images 1, 5 and 14 days after unilateral
optic nerve crush (left eye) and injection of SPION-labeled
BMMCs. The signal of the iron in the transplanted cells is
more evident one day after injection and it appears as a
hypointense, dark spot close to the lens (arrows). This can be
seen in the coronal, horizontal and sagittal planes. Five days
after transplantation, we can note a decrease in the hypoin-
tense signal, which is more evident in the coronal plane.
Finally, 14 days after the injection, the hypointense signal
derived from the transplanted cells is almost absent, suggest-
ing that there is a fast decrease in the number of BMMC cells
in the eye.
2.6. A second BMMC injection does not prolong RGC
survival 28 days after injury
As the number of cells that remain in the eye 14 days after
injection is very small, we speculated that the transitory
effect of BMMC transplantation on RGC survival could be
related to the short persistence of these cells in the eye.
Therefore, we performed a second injection of BMMCs 7 days
after the ﬁrst one to verify if a new exposure to the
transplanted cells could prolong RGC survival. Untreated
animals received two injections of saline at the same time
points. Animals were analyzed 28 days after optic nerve
crush.
Twenty-eight days after injury, we can notice that there is
no statistically signiﬁcant difference between the animals
that received two injections of BMMCs (Fig. 7(B)) when
compared to animals that received two injections of saline
(Fig. 7(A)). Animals that received two saline injections (n¼8)
had a mean of 12.7671.83% RGCs and animals that received
two BMMC injections (n¼14) had a mean of 16.0171.56%
RGCs compared to contralateral uninjured retinas. Fig. 7(C)
shows the quantiﬁcation of the data. This demonstrates that
a second injection of BMMC does not prolong RGC survival.
Besides quantifying neuronal survival on these animals,
we also analyzed the axonal outgrowth by GAP-43 staining.
As previously done, we quantiﬁed the number of GAP-43þ
b r a i n r e s e a r c h 1 5 8 7 ( 2 0 1 4 ) 5 4 – 6 860axons located at 0.5, 1.0, 1.5 and 2 mm from the injury site.
Animals that received two injections of saline had a median
of 264.1 axons per nerve at 0.5mm (n¼6); 176.9 axons at 1 mm(n¼6); 27.2 axons at 1.5 mm (n¼6) and 0 axons at 2 mm (n¼6)
from the crush site. Animals that received two injections of
BMMC had a median of 967.7 axons per nerve at 0.5 mm
Fig. 6 – The transplanted cells do not remain in the eye for a long period of time (A)–(D) Cells were labeled with FeraTrackTM for
3 h, ﬁxed and immunostained with anti-dextran antibody to identify dextran coated particles (A), red). (B) nuclei stained with
TO-PRO-3 (green). (C) Bright ﬁeld. (D) Merged imaged of (A) and (B). (E) One day after nerve injury and BMMC injection, these
cells are found in the vitreous body as dextran-positive cells (red). Nuclei were stained with TO-PRO-3 (green). (F) Detection of
FeraTrack-labeled BMMCs by in vivo MRI. BMMCs were labeled with FeraTrackTM and injected in the vitreous body of the left
eye after optic nerve crush. In the Figure, we can see representative images of coronal, horizontal and sagittal planes at
different survival times. Arrows indicate hypointense (black) spots corresponding to FeraTrack-labeled cells in the vitreous
body of the left eye. We can see that 14 days after the injection only a few cells remain in the eye. Scale bar: 50 μm (A)–(D) and
250 μm (E).
b r a i n r e s e a r c h 1 5 8 7 ( 2 0 1 4 ) 5 4 – 6 8 61(n¼8); 620.3 axons at 1 mm (n¼10); 124.9 axons at 1.5 mm
(n¼10) and 20.3 axons at 2 mm (n¼10) from the crush site.
The two injections of BMMC generated a 3.6-fold signiﬁcant
increase (po0.05) in the number of GAP-43þ axons at 0.5 mm
from the crush site, a 3.5-fold signiﬁcant increase (po0.05) in
the number of GAP-43þ axons at 1 mm from the crush site and
a 4.6-fold signiﬁcant increase (po0.05) in the number of GAP-
43þ axons at 1.5 mm from the crush site when compared to two
saline injections. At the distance of 2 mm from the injury site,
there was no statistically signiﬁcant difference between the two
conditions (p40.05). Fig. 7(D) shows the quantiﬁed data.
Interestingly, comparing the median of the number of
axons located at 1 mm from the crush site after one (454.9Fig. 5 – Analysis of BMMC transplanted cells by sintigraphy and
shortly after injection, BMMCs were labeled with 99mTc prior to
were performed in these animals for qualitative biodistribution i
a high-resolution collimator and diagnostic CT 1 h after injection
can see that the 99mTc activity is restricted to the eye. (D) In the
activity in other organs. (E) 99mTc signal combined with CT imag
transplantation and analyzed by ﬂow cytometry. Images show
experiments. (F) CellTraceþ BMMCs before injection were 99.7%.
had no CellTraceþ cells (0.00%). (H) and (I) CellTraceþ cells 1 day
dramatically reduced to 0.1470.1% after 3 days (I).axons) or two BMMC injections (620.3 axons), we can notice
that after two injections, there is a higher number of axons at
this distance. The difference is statistically signiﬁcant
(po0.05), demonstrating that a second dose of BMMC
improves the effect of a single dose on axonal regeneration
(Supplementary Fig. 1A).
However, comparing the median of the number of axons
located at 1mm from the crush site after one (46.73 axons) or
two saline injections (176.9 axons), there is also a statistically
signiﬁcant difference (po0.05) (Supplementary Fig. 1(B)), sug-
gesting a possible role of inﬂammation in these results.
To verify that a second injection of BMMC increased the
persistence of the cells in the eye, we labeled the BMMCsﬂow citometry. In order to trace the fate of transplanted cells
transplantation. Whole-body and localized scintigraphies
n a dedicated small animal SPECT/CT camera equipped with
. In the sagittal (A), coronal (B) and horizontal (C) planes, we
transversal plane of the torax, we can note the absence of
e. (F)–(I) BMMCs were labeled with CellTrace prior to
representative dotplots and the mean 7 SEM of 3 distinct
(G) Retina and vitreous of an uninjured and non-injected eye
after injection in the injured eye were 1.370.66% (H) and
Fig. 7 – A second BMMC injection does not prolong RGC survival. Attempting to increase RGC survival in a long term, we
performed a second BMMC transplantation 7 days after the ﬁrst one. The untreated group received two saline injections in the
same time points. (A)–(B) Confocal projection images of ﬂat-mounted retinas labeled with Tuj1 antibody 28 days after optic
nerve crush and two saline (A) or BMMC (B) injections. We can note that there is a reduction in the number of surviving RGC
both in the untreated (A) and the treated group (B). (C) Quantiﬁcation of the ganglion cell survival 28 days after the crush. (D)
Quantiﬁcation of the axonal outgrowth (GAP-43þ axons) 28 days after the crush. Scale bar: 50 μm.
b r a i n r e s e a r c h 1 5 8 7 ( 2 0 1 4 ) 5 4 – 6 862again with SPION and analyzed the animals that received two
BMMC injections by in vivo MRI 1, 8 and 14 days after optic
nerve crush. Fig. 8 shows MRI images of coronal, horizontal
and sagittal planes 1, 8 and 14 days after unilateral optic
nerve crush (left eye). Labeled cells were injected at the same
day of optic nerve crush and 7 days after the ﬁrst injection.
Similar to what we observed after a single BMMC injection,
the signal of the transplanted cells is more evident one day
after injection and it decreases in the subsequent days. By
comparing Fig. 8 to Fig. 6(F), we can notice that two weeks
after optic nerve crush, the iron signal from the SPION BMMC
is very similar after one (Fig. 6(F)) or two injections (Fig. 8),
suggesting that a second dose of BMMC does not increase
persistence of the transplanted cells in the eye.3. Discussion
In previous work, our group demonstrated that BMMC trans-
plantation increases RGC survival and axonal outgrowth 14
days after optic nerve crush (Zaverucha-do-Valle et al., 2011).
In the present work, we investigated if this effect wassustained for a longer period of time and we analyzed the
effect of a second injection of BMMC.
Although other studies have used bone marrow-derived
mesenchymal cells for cell therapy in the visual system
(Johnson et al., 2010; Levkovitch-Verbin et al., 2010), we used
BMMCs because these cells can be easily transplanted from
donor to recipient without cell culture, making translation to
clinic simpler. Another potential advantage of using these
cells is that they are a heterogeneous population and cell
types other than the mesenchymal cells may also play a role
in the treatment.
We have previously characterized that the BMMC fraction
we inject has around 24% of lymphocytes, 55% of granulo-
cytes and 16% of monocytes (Gubert et al., 2013) and these
cells can release cytokines and/or growth factors in response
to stimulus. Our group has demonstrated, for example,
increased in BDNF and FGF-2 levels after global ischemia
and sciatic nerve injury respectively in animals that received
BMMC transplantation (Ribeiro de Resende et al., 2012; Gubert
et al., 2013). It is also possible that paracrine interactions
between mesenchymal cells and other bone marrow-derived
cells might be beneﬁcial.
Fig. 8 – A second BMMC injection does not prolong the
persistence of the transplanted cells in the host eye.
Detection of FeraTrack-labeled BMMCs by in vivo MRI. In the
Figure, we can see representative images of coronal,
horizontal and sagittal (ipsilateral to the injury) planes at
different survival times. Arrows indicate hypointense (black)
spots corresponding to FeraTrack-labeled cells in the
vitreous body of the left eye.
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days after optic nerve crush. We observed that BMMC-treated
animals had a higher number of axons located at 0.5, 1 and
1.5 mm from the crush site when compared to untreated
animals at this time point. If we compare the median of the
number of axons located at 0.5, 1.0 and 1.5 mm from the
crush site 14 days (Zaverucha-do-Valle et al., 2011) and 28
days after optic nerve crush and cell therapy, we can notice
that the median is always higher at the longest time point
(423.8 axons versus 819.2 axons at 0.5 mm; 174.6 axons versus
454.9 at 1 mm; 77.1 axons versus 304.5 axons at 1.5 mm). This
comparison suggests that the axons continue to grow from 14
to 28 days after injury.
However, 28 days after optic nerve crush, the number of
RGCs that remained alive was similar in treated and
untreated animals, suggesting that the BMMC effect on RGC
survival was transient. This is not the ﬁrst report of a therapy
that promotes axonal outgrowth without promoting retinal
ganglion cell survival. Yin and co-workers, for example,
showed that oncomodulin released from microspheres pro-
motes regeneration in the optic nerve, but the protein does
not improve neuronal survival in vitro (Yin et al., 2006).
It has also been shown that FGF-2 up-regulation in adult
RGCs by gene delivery has a transient effect on RGC survival
following optic nerve crush (Sapieha et al., 2003). Fourteen
days after the injury, the authors demonstrated increased
axonal outgrowth following FGF-2 up-regulation in spite of
low RGC survival (Sapieha et al., 2003). There are different
reports showing that promoting RGC survival is not enough
to improve axonal regeneration (Lodovichi et al., 2001; Inoueet al., 2002), suggesting that neuronal survival and axonal
outgrowth follow different pathways.
In order to investigate possible factors that could be
responsible for the BMMC effect, we analyzed the mRNA
levels of FGF-2, VEGF, CNTF, BDNF and oncomodulin and we
demonstrated an increase in FGF-2 mRNA levels 1 day after
optic nerve crush. This increase is still evident 14 days after
optic nerve crush (Zaverucha-do-Valle et al., 2011), but after
28 days, the FGF-2 levels are very similar in treated and
untreated animals. Therefore, the effects of BMMC transplan-
tation on RGC survival could be related to FGF-2 release and,
consequently, would be transitory.
Analyzing the permanence of transplanted cells in the eye
by MRI, we demonstrated that the number of BMMCs in the
eye is very low 14 days after transplantation. Therefore, the
transitory effects on neuroprotection could be associated to
the short persistence of the transplanted cells in the eye that
is probably due to their low integration into the retina. This
low integration has been reported in different models
(Yu et al., 2006; Johnson et al., 2010).
Short-term effects on RGC survival have also been shown
after cell therapy in other models. Wu and co-workers, for
example, have shown increased neuronal survival 7 days
after optic nerve transection and injection of olfactory
ensheathing cells into the ocular stumps, but these effects
were not sustained after 14 days (Wu et al., 2010).
In an attempt to prolong the effects on RGC survival, we
performed a second injection of BMMC 7 days after the ﬁrst
one. We veriﬁed that even with the second dose, there was
still no statistically signiﬁcant difference on RGC survival
between treated and untreated animals. That was not the
ﬁrst report showing that multiple cell injections did not
improve the therapy outcome. Omori and co-workers, for
example, injected a single dose or multiple doses of human
mesenchymal stem cells systemically after cerebral artery
occlusion in rats and veriﬁed that the single dose had the
greatest therapeutic effect when compared to the multiple
injections (Omori et al., 2008). Similarly, Zhang et al. (2011)
showed that multiple injections (either two or three injec-
tions) of bone marrow cells did not decrease the infarct size
in a model of myocardial infarction .
A possible explanation for the lack of effect of the second
injection on RGC survival is that the window of treatment is
very narrow since the RGCs activate apoptotic pathways and
start to die within the ﬁrst days after optic nerve injury.
Therapy should act on early time points to avoid the entrance
of cells in the degenerative process. Once the cells are com-
mitted to die, it might be too late to promote survival. Our
results suggest that BMMC transplantation does not prevent cell
death but, instead, delays it, explaining why RGCs are more
preserved 14 days after the lesion but not after 28 days. For that
reason, giving an additional injection of BMMCs 7 days after the
ﬁrst treatment may be too late to improve survival.
Interestingly, although the second BMMC injection did not
improve RGC survival, we can notice an effect on axonal
outgrowth. By comparing the median of the number of axons
located at 1mm from the crush site after one or two BMMC
injections, there is a higher number of axons after two
injections. This demonstrates that a second dose of BMMC
improves the effect of a single dose on axonal regeneration.
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saline also generates a higher number of axons at 1 mm from
the crush site than one injection of saline. This suggest that
although we excluded from the analysis animals that had
lens injury, the additional injection of vehicle by itself
improved axonal outgrowth, possibly by inducing a low
inﬂammatory process. Therefore, a single injection of BMMCs
followed by a second injection of vehicle may be a good
option to improve axonal regeneration. However, it is impor-
tant to mention that performing a second injection increases
the chances of injuring the lens and/or damaging the retina
and the risk should be considered for clinical purposes.
In conclusion, cell therapy using bone marrow mono-
nuclear cells improves axonal outgrowth and this effect is
sustained at least up to 28 days after optic nerve crush. In
previous work, we demonstrated that a few axons were able
to reach the brain 60 days after treatment, suggesting that the
BMMC transplantation on axonal outgrowth is prolonged
(Zaverucha-do-Valle et al., 2011). However, at this time point,
RGC survival is similar in untreated and treated animals,
suggesting that neuronal survival and axonal regeneration
follow different pathways. A second dose of BMMC could not
rescue the retinal ganglion cells. Therefore, in order to
achieve long-term effects on neuroprotection, it would be
important to ﬁnd other types of cells that could persist in the
tissue for a longer period of time.
It has been demonstrated that bone marrow-derived
mesenchymal cells can survive in the brain for at least 60
days (Moraes et al., 2012) and in the vitreous cavity for at least
5 weeks (Johnson et al., 2010). Both BMMC and mesenchymal
cells express growth factors ((Yu et al., 2006; Li et al., 2009;
Zaverucha-do-Valle et al., 2011; Ribeiro de Resende et al.,
2012; Johnson et al., 2014) and both populations have been
used in different models with similar results ((de Vasconcelos
Dos Santos et al., 2010; Lindoso et al., 2011; Abreu et al., 2013).
Therefore, it would be interesting to analyze if mesenchymal
cells could prolong RGC survival.
Alternatively, it would also be interesting to combine cell
therapy using BMMC with other strategies to increase RGC
survival, such as lens injury (Fischer et al., 2000; Leon et al.,
2000) zymosan injection (Yin et al., 2003), bcl-2 overexpres-
sion (Chierzi et al., 1999) or PTEN and SOCS-3 deletion (Park
et al., 2008; Smith et al., 2009; Sun et al., 2011).4. Experimental procedure
4.1. Bone marrow mononuclear cell extraction
All the experiments were performed according to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and the protocols were approved by the Committee
for the Use of Experimental Animals of our Institution. Bone
marrow mononuclear cell extraction was performed as pre-
viously described (Zaverucha-do-Valle et al., 2011; Vasconcelos-
dos-Santos et al., 2012). Brieﬂy, the bone marrow was extruded
from their tibias and femurs of syngeneic donor Lister-hooded
adult rats. The isolated bone marrow was dissociated in DMEM-
F12 (GIBCO BRL, Grand Island, NY, USA) and separated by
density gradient on Histopaque 1083 (Sigma, St. Louis, MO,USA). The mononuclear fraction was then collected, washed
three times with phosphate-buffered saline (PBS) and resus-
pended in saline (0.9% NaCl).
4.2. Optic nerve crush and intraocular injections
Optic nerve was crushed in a procedure similar to previously
described (Berry et al., 1996). Brieﬂy, Lister-hood adult rats (3–
5 months old) were anesthetized with ketamine (50 mg/kg)
and xylazine (5 mg/kg) and an incision was made in the skin
under a stereoscopic microscope. The left optic nerve was
exposed, the epineuriumwas opened and the optic nerve was
crushed 1 mm behind the eye with angled tweezers for 15 s
avoiding injury to the ophthalmic artery. Immediately after
the optic nerve crush, we injected 5 μl of saline or 5106
BMMCs ressuspended in 5 μl of saline using a 5-μl Hamilton
syringe avoiding injury to the lens. Animals that received two
injections of saline or BMMCs had the ﬁrst injection imme-
diately after the crush and the second injection after 7 days.
The second injection was always performed in the side of the
eye opposite to the ﬁrst injection to avoid further damage.
Lesion was always performed in one eye and the contral-
ateral eye was used as control. Animals were kept in a warm
cage for anesthesia recovery and received food and water ad
libitum after being transferred to animal facility.
4.3. BMMC labeling with CellTrace and ﬂow cytometry
For ﬂow cytometry analyses, BMMCs were labeled with the
ﬂuorescent dye CellTrace™ FarRed DDAO-SE (2.5 mg/mL) (Invi-
trogen) for 40 min at 37 1C and 5%/95% CO2/air. After incuba-
tion, cells were washed three times in PBS and prepared for
administration as described previously.
One and 3 days after optic nerve crush and BMMC trans-
plantation, animals were euthanized. The vitreous body and
the retina were isolated and retina was dissociated using a
papain digestion protocol. Brieﬂy, retinas were incubated in
papain solution (Worthington Biochemical Corporation, Lake-
wood, NJ, USA) for 30min at 37 1C and 5%/95% CO2/air. Cells
were then washed there times in DMEM-F12 (GIBCO BRL,
Grand Island, NY, USA) and resuspended in PBS for ﬂow
cytometry analyses. Cells were incubated with DAPI to verify
cell viability and were analyzed in a BD FACS Aria II ﬂow
cytometer (BD Biosciences). Acquired data were analyzed by
FlowJo v.7.6.4 software (FlowJo, USA).
4.4. BMMC labeling with 99mTechnetium (99mTc) and
in vivo scintigraphy
For short-term track of the transplanted cells, BMMCs were
labeled with 99mTc following protocols described previously
(Carvalho et al., 2008; Quintanilha et al., 2008; Vasconcelos-
dos-Santos et al., 2012). Brieﬂy, 500 μL of sterile SnCl2 solution
was added to the cell suspension in 0.9% NaCl and the
mixture was incubated at room temperature for 10 min.
Then, 5 mCi of 99mTc was added and the incubation contin-
ued for another 10 min. After centrifugation (500g for
5 min), the supernatant was removed and the cells were
resuspended in 0.9% NaCl. Viability of the labeled cells
was assessed by the trypan blue exclusion test, and was
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efﬁciency (%) was calculated by the activity in the pellet
divided by the sum of the radioactivity in the pellet plus
supernatant, and was estimated to be greater than 90% in all
cases. A total of 5x 106 99mTc-BMMCs were injected direct into
the vitreous body of adult rats as previously described. Whole-
body and localized scintigraphies were performed in these
animals 1 h after injection for qualitative biodistribution in a
dedicated small animal SPECT/CT camera (Triumph, Gamma-
medica ideas, Canada) equipped with a high-resolution colli-
mator and diagnostic CT.
4.5. BMMC labeling with SPION and in vivo magnetic
resonance imaging (MRI)
For long-term track of the transplanted cells, BMMCs were
labeled with superparamagnetic iron oxide (SPION) particles
(FeraTrack Contrast Particles, Milteny Biotec, Bergisch Glad-
bach, Germany). We used the protocol described by the
manufacturer and cells were incubated with the particles
for 3 h, at 37 1C and 5%/95% CO2/air. After this period of time,
cells were washed three times with PBS and were resus-
pended in saline for further injection.
BMMCs labeled with SPION were tracked in vivo by MRI
scanning 1, 5, 9, 14 or 16 days after optic nerve crush and cell
transplantation. For MRI, animals were anesthetized by
intraperitoneal injection of ketamine (50 mg/Kg) and xylazine
(15 mg/Kg) and positioned in the MRI coil. Images were
acquired in a 7- T magnetic resonance scanner (7T/210
horizontal Varian scanner, Agilent Technologies, Palo Alto,
CA, USA), using fast spin echo (FSE) proton density (PD)
sequences (matrix: 192x192, slice thickness: 0.5 mm; 15
continuous slices) in the axial (TR/TE: 1500/11 ms; ﬁeld of
view: 3030 cm), coronal (TR/TE: 2100/11 ms; ﬁeld of view:
3030.5 cm) and sagittal (TR/TE: 1500/11 ms; ﬁeld of view:
3030.5 cm) planes. Data processing was performed using
MRIcron.
4.6. Immunohistochemistry
Twenty-eight days after optic nerve crush, animals were
euthanized and perfused with saline followed by 4% paraf-
ormaldehyde and 4% paraformaldehyde with 10% sucrose.
Eyes were then removed with the optic nerve attached. For
retinal ganglion cell survival analysis, retinas were dissected,
ﬂat mounted and washed 3 times with 0.1% Triton X-100 in
PBS. Flat-mounted retinas were then incubated in 5% normal
goat serum (Sigma) in PBS at room temperature for 1 h and in
Tuj1 antibody (1:500 in 0.1% Triton X-100 in PBS, Covance Inc.,
USA) at room temperature for 3 h followed by incubation at
4 1C overnight. The retinas were washed in PBS and then
incubated with Cy3-conjugated goat anti-mouse IgG (1:1000,
Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA) for
2 h at room temperature. After washing (three times in PBS),
retinas were mounted with VectaShield (Vector, Burlingame,
CA, USA) onto glass slides and photographed on a Zeiss
Axiovert 200M microscope equipped with an Apotome slide
(Zeiss). To quantify RGC survival, we took 10 pictures of
regions radially distributed at 1 mm from the optic disc, using
a 400.75 NA objective. Counts were made by a blindobserver. The statistical analysis was done using GraphPad
Prism 5.02 (1992–2004 GraphPad Software, Inc.), using an
unpaired two- tailed t-test.
For axonal outgrowth and basic ﬁbroblast growth factor
(FGF-2) expression analysis, nerves and eyes were embedded
in optimal cutting temperature (OCT) compound (Tissue-Tek,
Sakura, Japan) and cut longitudinally on a cryostat (Leica CM
1850, Microsystems Nussloch GmbH, Germany) at 14–20 μm
thickness. Sections were collected on gelatin-coated slides.
For immunohistochemistry analysis, sections were washed 3
times in PBS, incubated in 5% normal goat serum (Sigma) in
PBS for 30 min at room temperature and incubated with
primary antibodies overnight at 4 1C. Sections were then
washed 3 times and incubated with the appropriate second-
ary antibodies for 2 h at room temperature. Nerves were
stained with anti-growth-associated protein 43 (GAP-43) anti-
body (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
followed by Cy3-conjugated goat anti-rabbit IgG (1:1000,
Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA) or
Alexa 488-conjugated goat anti-rabbit IgG (1:200; Invitrogen
Inc., Carlsbad, CA, USA). Retinas were stained with anti-FGF-2
antibody (1:100, EMD Millipore, Germany) followed by Cy3-
conjugated goat anti-mouse IgG (1:1000, Jackson ImmunoR-
esearch Lab. Inc., West Grove, PA, USA). In some cases the
tissues were incubated with Sytox Green (500 nM; Invitrogen),
bisbenzimide (0.01% in PBS, Sigma) or TO-PROs-3 (1:1000,
Invitrogen Inc) for nuclei counterstaining. After washing
(three times in PBS), the slides were mounted with Vecta-
Shield (Vector Laboratories) and analyzed by confocal micro-
scopy (Zeiss, LSM 510 META).
To visualize the SPIONs in the transplanted cells, we used
an antibody against their dextran-coating. For that, both
retinas of transplanted animals and dissociated cells plated
on glass coverslips were washed 3 times with 0.1% Triton
X-100 in PBS and incubated in 5% normal goat serum (Sigma)
in PBS for 30 min at room temperature. The primary antibody
(anti-dextran, 1:1000, StemCell Technologies, Vancouver, BC,
Canada) was incubated overnight at 4 1C. After that, the cells
or the tissue were washed with 0.1% Triton X-100 in PBS and
incubated with the secondary antibody (Alexa488-anti-
mouse, 1:1000, Invitrogen Inc) and TO-PROs-3 to label nuclei
(1:1000, Invitrogen Inc) for 2 h at room temperature. After
washing, the slides were mounted with VectaShield (Vector
Laboratories) and analyzed by confocal microscopy (Zeiss,
LSM 510 META).
4.7. Fluorescence intensity quantiﬁcation
Twenty-eight days after optic nerve crush, retinas from
untreated and BMMC-treated animals were labeled with
anti-FGF-2 antibody and nuclei were counterstained with
TO-PROs-3 as described above. For ﬂuorescence intensity
quantiﬁcation, Z stack images from the central and periph-
eral retinas were acquired using a confocal microscope (Zeiss
LSM 510 Meta). We analyzed two images from each slice and
three slices per animal. All the immunostaining reactions
were performed simultaneously. Individual slices of each
stack were analyzed using Image J software (NIH). Fluores-
cence intensity was measured separately in the nerve ﬁber
layer (NFL) and ganglion cell layer (GCL), in the inner
b r a i n r e s e a r c h 1 5 8 7 ( 2 0 1 4 ) 5 4 – 6 866plexiform layer (IPL) and in the inner nuclear layer (INL),
outer plexiform layer (OPL) and outer nuclear layer (ONL). We
quantiﬁed only the FGF-2 labeling signal and the nuclei
stained was used for identiﬁcation of retinal layer. The
average mean gray value per stack of BMMC-treated and
untreated animals were acquired and used for statistical
analysis. Quantiﬁcations were performed by a blind observer.
4.8. Retrograde labeling of retinal ganglion cells
In a different set of animals, retinal ganglion cell survival was
quantiﬁed by retrograde labeling using the lipophilic tracer
DiI (1,10-dioctadecyl-3,3,3,30-tetramethylindocar- bocyanine
perchlorate, Invitrogen) (n¼16). DiI labeling was performed
as previously described (Zaverucha-do-Valle et al., 2011).
Brieﬂy, 4 μl of DiI (2.5% in dimethylformamide, Sigma) was
delivered stereotaxically (6.3 mm posterior from Bregma;
1.2 mm lateral and 3.5 mm ventral) bilaterally into the super-
ior colliculi 7 days before the optic nerve crush. For quanti-
ﬁcation of RGC survival, 28 days after optic nerve crush,
animals were euthanized and the retinas were dissected
without ﬁxation, ﬂat mounted, and ﬁxed onto gelatinized
glass slides with 4% paraformaldehyde for 15 min at room
temperature. Retinas were then washed three times with PBS,
covered with coverslips and photographed on a Zeiss Axio-
vert 200M microscope equipped with structured illumination
microscopy (Apotome) and a MRm digital camera (Zeiss).
4.9. Ganglion cell axon labeling and quantiﬁcation of axon
outgrowth
For retinal ganglion cell axon labeling, we injected 4 μl of
Cholera Toxin B subunit conjugated to Alexa488 (CTB) (Invi-
trogen, 0.2% diluted in PBS with 1% DMSO) into the vitreous
body 26 days after optic nerve crush. Two days after injection,
animals were perfused, optic nerves were dissected and
histological preparation was similar to what was described
above.
For quantiﬁcation of axon outgrowth, we counted the
number of GAP-43þ axons or CTB-labeled axons located at
0.5, 1, 1.5 and 2 mm from the injury site. The total number of
axons per nerve was calculated by using the formula described
by Leon and co-workers (Leon et al., 2000). Statistical analysis
was done using GraphPad Prism 5.02 (1992–2004 GraphPad
Software, Inc.) using a nonparametric unpaired one-tailed
Mann–Whitney test.
4.10. Real Time quantitative PCR
Analysis of mRNA levels changes was carried out by real-time
quantitative polymerase chain reaction. Total mRNA was
obtained from retina by TRIzol reagent (Invitrogen) according
to the manufacturer's protocol and stored at –70 1C. A total of
2 μg RNA was treated with DNAse Ampliﬁcation grade I (Invi-
trogen), to remove genomic DNA contaminant, and then
reverse transcribed to complementary DNA (cDNA) with Super-
script II Reverse Transcriptase s (Invitrogen) and Oligo-dT18
(Invitrogen). Reactions were performed in 10 uL with ﬁnal
concentration of 1 of Power SYBR Green PCR Master Mix
(Applied biosystems), 0.5 uM of each forward and reverseprimers and completed 2.5 uL of cDNA diluted ﬁve folds.
Reactions were carry out in Rotor Gene-Q 6000 thermocycler
(Qiagen) with hot-start stage step of 10 min at 95 1C followed by
45 cycles of 20s at 95 1C and 40 s at 60 1C. The dissociation curve
was used to determine the PCR efﬁciency and speciﬁc ampliﬁ-
cation and primer-dimer formation. The GAPDH mRNA levels
were used as reference for normalization reactions. Sequence
primers used were: BDNF 50- ATGGTTATTTCATACTTCGGTTGC
and 50- CCGTGGACGTTTGCTTCTT; FGF2 50-AGGAAGATG-
GACGGCTGCTG and 50-GCCCAGTTCGTTTCAGTGCC; CNTF 50-
TGAAGACAGAAGCAAACCAGC and 50-AGAACGGCTACA-
GAGGTCCC; VEGF 50-GAGTATATCTTCAAGCCGTCCTGT and 50-
ATCTGCATAGTGACGTTGCTCTC; GAPDH 50-ATCAAGAAGGT-
GGTGAAGCAGG and 50-AGGTGGAAGAGTGGGAGTTGCT. Fold-
expression was calculated using the Delta delta cycle threshold
(DDCt) method (Livak and Schmittgen, 2001).Acknowledgments
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